F-star Therapeutics to Present at Upcoming Investor Conferences
Company Leadership will Speak at Ladenburg Thalmann 2021 Healthcare Conference and the William Blair 2021 Biotech Focus Conference
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that the company will participate in two virtual investor conference events next week.
Details are as follows:
Ladenburg Thalmann Healthcare Conference 2021
Fireside chat with F-star CEO, Eliot Forster
Date: Tuesday, July 13, 2021
Time: 9:30 a.m. to 10:00 a.m. ET
Management will be available for 1:1 meetings Tuesday, July 13th
William Blair Biotech Focus Conference 2021
Neil Brewis, CSO, will speak on a panel discussing “Moving Beyond Monoclonals: The Potential of Multispecific Therapies.”
Date: Wednesday, July 14, 2021
Time: 11:20 a.m. to 12:20 p.m. ET
Management will be available for 1:1 meetings Wednesday, July 14th
About F-star Therapeutics, Inc.
F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit and follow us on and .
For further information, please contact:
For investor inquiries
Lindsey Trickett
VP Investor Relations & Communications
For media inquiries
Helen Shik
Shik Communications LLC
